Share this release
Share on: Twitter
Share on: Facebook
Share on: LinkedIn
Latest news
York,
26
June
2015

Further Medicare Coverage Approval for DermaPure®

Delivering on the strategy: DermaPure® now available to 20.7 million Medicare beneficiaries

Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces it has secured approval from the Noridian Healthcare Solutions and Palmetto GBA Medicare administrators for DermaPure® reimbursement.

The approval from Noridian Healthcare Solutions and Palmetto GBA means that DermaPure® is now available to 20.7 million Medicare beneficiaries across 30 states and follows previously announced approvals from the Novitas Solutions and CGS Administrators jurisdictions in 2015.

Gaining Medicare approval for DermaPure® across the United States is a key element of Tissue Regenix’s strategy for full commercialisation of the product and allows the company to access the largest potential group of US patients who would be unable to benefit from Tissue Regenix products without it.

The Medicare programme in the United States is a national social insurance programme which provides health insurance for citizens aged 65 and over. It is administered by bodies such as Noridian Healthcare Solutions and Palmetto GBA, each one with their own jurisdiction of states. When coverage is approved it enables medical establishments to purchase and seek reimbursement for products used to treat post-acute and outpatients who are beneficiaries of the Medicare initiative.

Antony Odell, CEO of Tissue Regenix
We are thrilled with DermaPure’s® performance in 2015. In the space of just four months the product has gained approval for coverage in over half of the American states via what is a highly rigorous and intensive selection process.


This is further evidence of both the continued strong clinical performance of DermaPure® and Tissue Regenix delivering on its clearly defined strategy for full commercialisation of the product in the US.


While it is hard to predict the time frame for further approvals, we are confident that the successful clinical outcomes of DermaPure® across an ever widening pool of patients stands us in good stead for gaining additional coverage.

 
Antony Odell, CEO of Tissue Regenix